日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌：随机3期PHILA试验的长期生存结果

期刊:Bmj-British Medical Journal
影响因子:42.7
doi:10.1136/bmj-2025-087259
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial

比瑞西尼联合氟维司群治疗内分泌进展后的晚期乳腺癌：BRIGHT-2 III期随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2026.0318
Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Hu, Yan; Wang, Qiuli; Duan, Xianghui; Yang, Fan; Wang, Li; Xu, Binghe
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study

腹泻与接受吡咯替尼治疗的 HER2 阳性晚期乳腺癌患者生存率之间的关联：来自真实世界 PRETTY 研究的里程碑式分析

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2026.104783
Li, Yiqun; Wang, Wenna; Tong, Zhongsheng; Wu, Xinhong; Cai, Li; Ouyang, Quchang; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Xu, Binghe
肿瘤
RET
HER2
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China

在中国开展的阿贝西利治疗HR+、HER2-乳腺癌患者的上市后前瞻性观察研究

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyag013
Ouyang, Quchang; Yuan, Peng; Liu, Jianxia; Teng, Yuee; Li, Zhihua; Ji, Xuening; Liu, Lina; Wang, Mopei; Zou, Liqun; Xu, Ling; Yang, Suisheng; Zhu, Zhenxin; Yang, Liu; Li, Jinnan; Liu, Qiang
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

AI and Big Data in Oncology: A Physician-Centered Perspective on Emerging Clinical and Research Applications

人工智能和大数据在肿瘤学中的应用：以医生为中心的视角探讨新兴的临床和研究应用

期刊:Cancer Innovation
影响因子:2
doi:10.1002/cai2.70047
Liu, Binliang; Shang, Qingyao; Li, Jun; Yao, Shuna; Ouyang, Meishuo; Wang, Yu; Luo, Sheng; Ouyang, Quchang
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR(+)/HER2(-) metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China

CDK4/6抑制剂在HR(+)/HER2(-)转移性乳腺癌中的真实世界疗效及预后因素：一项来自中国洞庭湖地区的多中心回顾性研究

期刊:Translational Breast Cancer Research
影响因子:1.4
doi:10.21037/tbcr-25-37
Liu, Binliang; Wu, Tao; Lu, Kaili; Chen, Jun; Zhou, Qiang; Liu, Liping; Tian, Can; Hu, Zhe-Yu; Tang, Yu; Ouyang, Quchang; Xie, Ning
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial

卡瑞利珠单抗联合化疗作为早期或局部晚期三阴性乳腺癌患者新辅助治疗的疗效比较：CamRelief随机临床试验

期刊:Journal of the American Medical Association
影响因子:55
doi:10.1001/jama.2024.23560
Chen, Li; Li, Hui; Zhang, Hao; Yang, Huawei; Qian, Jun; Li, Zhihua; Ren, Yu; Wang, Shu; Fu, Peifen; Yang, Hongjian; Liu, Yunjiang; Sun, Jing; Nie, Jianyun; Lei, Ruiwen; Yao, Yongzhong; Zhang, Anqin; Wang, Shouman; Ma, Xiaopeng; Ouyang, Zhong; Yang, Hongwei; Wu, Song-Yang; Cao, Shuo-Wen; Wang, Kun; Jiang, Aimei; Ouyang, Quchang; Pang, Da; Wei, Limin; Zha, Xiaoming; Shen, Yu; Qu, Xiangwen; Wu, Fei; Zhu, Xiaoyu; Wang, Zhonghua; Fan, Lei; Shao, Zhi-Ming
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

新型 CDK2/4/6 抑制剂 culmerciclib (TQB3616) 联合氟维司群治疗既往接受过治疗的 HR 阳性、HER2 阴性晚期乳腺癌：一项随机、双盲、3 期试验

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02475-6
Yin, Yongmei; Zhang, Qingyuan; Sun, Tao; Hao, Chunfang; Wang, Zhihong; Yang, Jin; Wang, Yongsheng; Shi, Yanxia; Sun, Jing; Ouyang, Quchang; Su, Haichuan; Wu, Jinsheng; Gan, Lu; Han, Meng; Gao, Liming; Wang, Xiaojia; Zhao, Bing; Li, Hui; Zhao, Jiuda; Yang, Hongwei; Ning, Fangling; Tian, Fuguo; Zhang, Juliang; Sun, Hongmei; Niu, Zhaofeng; Zong, Hong; Zang, Aimin; Wang, Xinshuai; Qian, Xinyu; Wu, Shikai; Nie, Jianyun; He, Lijia; Cheng, Ying; Hao, Yanrong; Zhai, Yi; Li, Huiping; Wang, Jingfen; Wei, Shihong; Li, Man; Liu, Yunjiang; Guo, Hongqiang; Hu, Qun; Liu, Lina; Han, Xinghua; Luo, Ruizhen; Ni, Mingli; Tang, Xianjun; Zhai, Zhenhua; Ding, Meiqian; Wang, Haibo; Shen, Peng; Wang, Xian; Liu, Lian; Chen, Wenyan; Liu, Gang; Cai, Zhengwen; Jiang, Zefei
肿瘤
HER2
肿瘤免疫
乳腺癌
CDK2
发表日期：2025
文献求助 收藏

ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer

ACE-Breast-02：一项比较 ARX788 与拉帕替尼联合卡培他滨治疗 HER2 阳性晚期乳腺癌的随机 III 期试验

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02149-3
Hu, Xichun; Zhang, Qingyuan; Wang, Leiping; Zhang, Jian; Ouyang, Quchang; Wang, Xiaojia; Li, Wei; Xie, Weimin; Tong, Zhongsheng; Wang, Shusen; Xu, Faliang; Sun, Tao; Liu, Wei; Chen, Zhendong; Wu, Jinsheng; Wang, Ying; Wang, Haixia; Yan, Min; Wang, Xinshuai; Wang, Jingfen; Cao, Feilin; Du, Yingying; Zhang, Yongqiang; Chen, Lilin; Lu, Ping; Sun, Sanyuan; Zhang, Ruiwen; Zang, Aimin; Nie, Xiuqing; Lei, Yuan
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

一项针对对标准疗法无效的不可切除的局部晚期或转移性实体瘤患者的sacituzumab tirumotecan 1/2期研究结果

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01705-2
Ouyang, Quchang; Rodon, Jordi; Liang, Yan; Wu, Xinhong; Li, Qun; Song, Lihua; Yan, Min; Tong, Zhongsheng; Liu, YunPeng; Wainberg, Zev A; Wang, Ying; Geng, Cuizhi; Ulahannan, Susanna V; Yu, Guohua; Sharma, Manish R; Wang, Xiang; Wang, Judy S; Spira, Alexander; Zhao, Weihong; Sanborn, Rachel E; Cheng, Ying; Wang, Xian; Liu, Gesha; Li, Yaling; Ge, Junyou; Chartash, Elliot; Akala, Omobolaji O; Yin, Yongmei
发表日期：2025
文献求助 收藏